combination therapy with glp-1 receptor agonist and sglt2 inhibitor Agonists Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined | Drugs Combining glucagon-like peptide-1 receptor agonists
Description
In 2004, for the first time in human study, Nikolaidis L.A, et al
60 Research has extensively examined the combined agonists of GLP-1 and GIP1-RA for their potential impact on diabetes management and weight reduction
Zepbound, developed by Eli Lilly and Co., is already approved as Mounjaro for improving blood sugar in adults with type 2 diabetes
J Biol Chem 289: 2723527245, 2014
There are ongoing studies including a large phase 3 trial underway to determine if semaglutide will meet any of these clinical endpoints for FDA approval
